Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the biological processes to develop technologies and products for biomedical research and therapy development.
Founded in 1999 by Jiwu Wang, Allele first broke ground as a R&D facility receiving multiple federal grants within the first two years. By 2002, Allele licensed its proprietary RNAi technology to the Promega Corporations. Over the next seven years Allele worked tirelessly to develop additional research tools including fluorescent proteins and efficient gene delivery platforms.
In 2009, Allele introduced the first nanoantibody research reagents to the US Market. Since then, Allele has received multiple federal grants to further develop its nanoantibody programs including a 2015 NIA/NIH grant to develop nanoantibodies against amyloid beta (Ab) for treating Alzheimer’s Disease as well as another NIA/NIH grant in 2017 to develop nanoantibodies against novel dementia-related targets in collaboration with Dr. Huaxi Xu’s lab at Sanford Burnham Prebys Medical Discovery Institute.
In late 2017, Allele published an original research article in Applied Immunohistochemistry & Molecular Morphology demonstrating the utility of modified nanoantibodies, in immunohistochemistry. Since then, Allele has seen extraordinary growth in its nanoantibody development program and looks to continue to set and meet more goals.